Heptares names new CMO
This article was originally published in Scrip
Heptares Therapeutics, a drug discovery company focused on the development of GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases, has named Dr Tim Tasker chief medical officer. Prior to joining the Hertfordshire, UK-based firm, Dr Tasker spent 20 years at GlaxoSmithKilne leading Phase I clinical research units, before setting up his own consulting firm.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.